What is 4D Molecular Therapeutics Capex-to-Operating-Income?
Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.
GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.
4D Molecular Therapeutics Capex-to-Operating-Income Historical Data
The historical data trend for 4D Molecular Therapeutics's Capex-to-Operating-Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of 4D Molecular Therapeutics's Capex-to-Operating-Income
For the Biotechnology subindustry, 4D Molecular Therapeutics's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
4D Molecular Therapeutics's Capex-to-Operating-Income Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, 4D Molecular Therapeutics's Capex-to-Operating-Income distribution charts can be found below:
* The bar in red indicates where 4D Molecular Therapeutics's Capex-to-Operating-Income falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.
4D Molecular Therapeutics Capex-to-Operating-Income Related Terms
Thank you for viewing the detailed overview of 4D Molecular Therapeutics's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.
4D Molecular Therapeutics (4D Molecular Therapeutics) Business Description
4D Molecular Therapeutics Inc a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built portfolio of gene therapy product candidates focused in three therapeutic areas: ophthalmology (intravitreal vector), cardiology (intravenous vector) and pulmonology (aerosol vector). It has three product candidates in clinical trials: 4D-125 for the treatment of X-linked retinitis pigmentosa in a Phase 1/2 clinical trial, 4D-110 for the treatment of choroideremia in a Phase 1 clinical trial, and 4D-310 for the treatment of Fabry disease in a Phase 1/2 clinical trial. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration, and 4D-710 for the treatment of cystic fibrosis lung disease.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FDMT has been successfully added to your 